Optical Activation of the Dorsal Horn of the Thoracic Spinal Cord Prevents Ventricular Arrhythmias in Acute Myocardial Ischemia-Reperfusion Rats

作者: Yong Wu, Zhongxu Luo, Zhengtao Hu, Kun Lv, Yinhua Liu, and Deguo Wang
杂志: Frontiers in Cardiovascular Medicine
Doi: https://www.doi.org/10.3389/fcvm.2022.753959
出版日期: 2022 Feb 7

论文中使用的产品/服务

Quotation shows PackGene:AAV9-containing Ca(2+)/calmodulin-activated protein kinase II-a (CaMKIIa) prompter with or without -hChR2(H134R) (PackGene Biotech, 10^13 vg/ml) was drawn up into a 10 μl Hamilton syringe with a glass pipette and pulled to a 20μm tip (Hamilton, Shanghai, Ch). Then AAVs (3 μl) were injected into the dorsal horn (0.5mm depth) under control by a stereotaxic micromanipulator through previously reported methods

Research Field:heart

AAV Serotype:AAV9

Targeted organ:heart

Animal or cell line strain:Adult male rats (Sprague Dawley)

询价

摘要

Background and ObjectivesSpinal cord stimulation can prevent myocardial ischemia and reperfusion arrhythmias, but the relevant neurons and mechanisms remain unknown. Thus, this study applied optogenetic techniques to selectively activate glutamatergic neurons at the thoracic spinal cord (T1 segment) for examining the anti-arrhythmia effects during acute myocardial ischemic-reperfusion.

文章链接

关于派真

作为一家专注于AAV 技术十余年，深耕基因治疗领域的CRO&CDMO，派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付，我们为全球客户提供一站式CMC解决方案，包括从早期概念验证、成药性评估到IIT、IND及BLA的各个阶段。

凭借我们独立知识产权的π-alpha^TM 293 细胞AAV高产技术平台，我们能将AAV产量提高多至10倍，每批次产量可达1×10¹⁷vg，以满足多样化的商业化和临床项目需求。此外，我们定制化的mRNA和脂质纳米颗粒（LNP）产品及服务覆盖药物和疫苗开发的各个阶段，从研发到符合GMP的生产，提供端到端的一站式解决方案。